Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway
- PMID: 2445959
Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway
Abstract
The influence of the dopaminergic system on the striatonigral tachykinin pathway was studied in male Fischer 344 rats. Activation of dopamine receptors by subacute administration of apomorphine (APO; 5 mg/kg s.c. twice daily for 7 days) significantly increased striatonigral substance P-like immunoreactivity (SP-LI; 73% over control in striatum, 63% over control in substantia nigra) and substance K-like immunoreactivity (49% over control in striatum, 15% over control in substantia nigra). The changes in striatonigral SP-LI were dose dependent (0.5-5 mg/kg), time related (one, three or seven daily injections) and region specific as changes were not observed in frontal cortex, hippocampus and hypothalamus. The increase of SP-LI and substance K-like immunoreactivity was completely prevented by the dopamine receptor blocker, haloperidol, which, by itself, caused a slight decrease of both peptide levels. Immunocytochemical staining revealed enhanced SP-LI in neurons restricted to striatal patches and fibers in substantia nigra pars reticulata after APO treatment as compared with SP-LI intensity in control. In order to understand the molecular mechanism underlying the APO-induced increase in the level of tachykinins, the abundance of messenger RNA coding for preprotachykinin was quantified by blot hybridization. It was found that subacute administration of APO increased the abundance of preprotachykinin messenger RNA in the striatum. These results suggest that stimulation of dopaminergic receptors leads to an acceleration of tachykinin biosynthesis. A single dose of APO (2.5 mg/kg s.c.) induced a slight but significant reduction in striatal SP-LI (82% of control). This result suggests that APO triggers the release of tachykinins.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Regulation of the metabolism of striatal dynorphin by the dopaminergic system.J Pharmacol Exp Ther. 1988 Jul;246(1):403-8. J Pharmacol Exp Ther. 1988. PMID: 2899169
-
Lithium increases rat striatal beta- and gamma-preprotachykinin messenger RNAs.J Pharmacol Exp Ther. 1989 Mar;248(3):1297-301. J Pharmacol Exp Ther. 1989. PMID: 2467980
-
Effects of haloperidol and clozapine on preprotachykinin-A messenger RNA, tachykinin tissue levels, release and neurokinin-1 receptors in the striato-nigral system.Synapse. 1990;6(1):1-9. doi: 10.1002/syn.890060102. Synapse. 1990. PMID: 1697986
-
The striatonigral substance P pathway and dopaminergic mechanisms.Ciba Found Symp. 1982;(91):281-95. doi: 10.1002/9780470720738.ch16. Ciba Found Symp. 1982. PMID: 6183075 Review.
-
A 25 year adventure in the field of tachykinins.Peptides. 2004 Mar;25(3):339-57. doi: 10.1016/j.peptides.2004.02.011. Peptides. 2004. PMID: 15134859 Review.
Cited by
-
Segregation of D1 and D2 dopamine receptors in the striatal direct and indirect pathways: An historical perspective.Front Synaptic Neurosci. 2023 Jan 19;14:1002960. doi: 10.3389/fnsyn.2022.1002960. eCollection 2022. Front Synaptic Neurosci. 2023. PMID: 36741471 Free PMC article. Review.
-
Control of tachykinin-evoked acetylcholine release from rat striatal slices by dopaminergic neurons.Naunyn Schmiedebergs Arch Pharmacol. 1993 Nov;348(5):445-9. doi: 10.1007/BF00173201. Naunyn Schmiedebergs Arch Pharmacol. 1993. PMID: 7509458
-
Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion.J Neural Transm (Vienna). 1996;103(3):249-60. doi: 10.1007/BF01271237. J Neural Transm (Vienna). 1996. PMID: 8739837
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous